RedFlag Index™ · #8 of 10 · NYSE: BMY

Bristol-Myers Squibb Company: enforcement record and regulatory exposure

Bristol-Myers Squibb Company scores 57 out of 100 on the RedFlag Index™ (November 2026), ranking #8 of ten tracked companies, with 4 documented cases of which 2 remain open.

Bristol-Myers Squibb has paid about $3.0 billion in tracked penalties since 2000 across 52 records. About $956 million of that is for competition-related violations.

2025: Bristol-Myers Squibb paid Hawaii $350 million over Plavix labeling and marketing. Sanofi paid the same amount.

2009: Bristol-Myers Squibb paid the FTC $2.1 million, the maximum then allowed, for hiding a Plavix patent side deal.

2007: Bristol-Myers Squibb paid $515.5 million over Abilify off-label promotion, kickbacks, and pricing.

DateMatterAmountStatus
November 2025Texas AG Plavix Medicaid fraud suit (with Sanofi)Open
May 9, 2025Hawaii Plavix labelling and marketing settlement$350mResolved
November 2019FTC Celgene acquisition order (Otezla divestiture)No penaltyResolved, order in force
April 2009FTC civil penalty over undisclosed Plavix patent deal$2.1mResolved
September 2007Abilify off-label, kickback and pricing settlement$515.5mResolved

Government enforcement only. Greyed rows are more than ten years old and excluded from scoring under the temporal decay rule.

  1. State Enforcement

    Texas sues Sanofi over free nurse and support services kickback allegations

    Texas Attorney General Ken Paxton has sued Sanofi-Aventis U.S. LLC, alleging that its Free Nurse Program and Support Services Program amounted to in-kind kickbacks to providers under the Texas Health Care Program Fraud Prevention Act. The state seeks more than $1 million in monetary relief, including civil penalties, and an injunction.

  2. Drug Pricing

    Federal judge rejects Merck's constitutional challenge to Medicare drug price negotiation

    Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia rejected Merck's First and Fifth Amendment challenge to the Inflation Reduction Act's Medicare drug price negotiation programme. Merck filed the first industry challenge to the programme in June 2023.